<DOC>
	<DOCNO>NCT01462500</DOCNO>
	<brief_summary>The purpose study determine pharmacokinetics miltefosine child adult cutaneous leishmaniasis plasma intracellularly , relation parasitologic response . The result provide pharmacologic base optimize use miltefosine treatment cutaneous leishmaniasis , provide knowledge base assess impact pharmacokinetic behavior child adult emergence drug resistance .</brief_summary>
	<brief_title>Pharmacokinetics Miltefosine Children Adults</brief_title>
	<detailed_description>An open-label phase IV clinical trial miltefosine , design evaluate intracellular plasma drug pharmacokinetics child adult use population pharmacokinetics design . Two study group define : 1 ) child 2-12 year age ( n=30 ) 2 ) adult 18-60 year age ( n=30 ) confirm parasitological diagnosis cutaneous leishmaniasis . The participant receive supervised standard treatment miltefosine : 1.8 - 2.5 mg/Kg weight 28 day . Miltefosine concentration determine plasma Peripheral Blood Mononuclear Cell ( PBMCs ) , 3 10ml peripheral blood sample child adult respectively . Sampling conducted pre-dosing day 0,1,15 29 treatment , month 1 , 2 , 3 6 post-treatment . A population pharmacokinetics analysis perform use non-linear model mixed effect software Nonlinear Mixed-effects Model ( NONMEM ) , R Piranha . Parasite burden determine 7SLRNA Quantitative Polymerase Chain Reaction ( qPCR ) Leishmania swab sample lesion extralesional tissue end treatment . The relationship pharmacokinetics parasite persistence/burden determine correlation analysis pharmacodynamic modeling .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Miltefosine</mesh_term>
	<criteria>Age : 212 year age , 1860 year age Weight great 10 kg Parasitologic confirmation cutaneous leishmaniasis Normal hepatic kidney function Pregnant lactate woman , woman plan conceive study reject use birth control method . Use drug antileishmanial potential previous 6 month , include pentavalent antimonials , amphotericin B , miltefosine , pentamidine Mucocutaneous visceral leishmaniasis For female child , menses evidence reproductive maturity</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Miltefosine</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>cutaneous leishmaniasis</keyword>
</DOC>